Prediction of Neonatal Chronic Lung Disease Using Body Fluid Exosomes and Therapeutic Effects of miR-21 Regulation

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K08233
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52050:Embryonic medicine and pediatrics-related
• Research Institution: Fukushima Medical University
• Principal Investigator: Hayato Go 福島県立医科大学, 医学部, 准教授 (30443857)
• Co-Investigator(Kenkyū-buntansha): 橋本 浩一 福島県立医科大学, 医学部, 准教授 (50322342)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: micro RNA / miR-21 / chronic lung disease / extracellular vesicles

Outline of Final Research Achievements

The purpose of this study was to test whether urinary Extracellular vesicles (EVs) miR-21 in preterm infants is a biomarker for CLD and to evaluate the role of miR-21 in CLD using miR-21 trangenic mice and wild-type CLD mice treated with miR-21 inhibitors. 21 in CLD using miR-21 trangenic mice and wild-type CLD mice treated with miR-21 inhibitors.
Although we were able to detect EVs in urine, we were not able to analyze the expression of miR-21. In mice, miR-21 inhibitor-treated and miR-21 heterozygous deficient mice showed significant weight gain at day 7 compared to controls.

Free Research Field

小児・新生児

Academic Significance and Societal Importance of the Research Achievements

我々は、これまで血中のEVs miR-21がCLDのバイオマーカになり得ることを証明できたが、尿中のEVs miR-21に関しては、コロナウイルス感染状況下で、バイオマーカーになり得るかまでを検討することができなかった。miR-21抑制剤やmiR-21欠損マウスを用いた研究では、miR-21ノックアウトマウスよりもmiR-21ヘテロ欠損マウスで、体重増加や呼吸機能の改善が得られたことから、miR-21をノックダウンすることで、治療効果が得られる可能性を見出せた。